Published in Am J Pathol on January 28, 2010
Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) (2010) 2.99
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PLoS One (2015) 1.46
Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) (2012) 1.38
Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int (2014) 1.18
Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci (2010) 1.17
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One (2011) 1.12
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol (2011) 1.11
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A (2013) 1.08
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett (2015) 1.05
Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int (2013) 0.99
Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolyte Blood Press (2014) 0.97
Screen of FDA-approved drug library reveals compounds that protect hair cells from aminoglycosides and cisplatin. Hear Res (2012) 0.96
Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics (2011) 0.92
Functional mechanotransduction is required for cisplatin-induced hair cell death in the zebrafish lateral line. J Neurosci (2013) 0.92
Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. Am J Physiol Renal Physiol (2013) 0.91
Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res (2011) 0.90
Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res (2014) 0.90
Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat (2012) 0.90
The cysteines of the extracellular loop are crucial for trafficking of human organic cation transporter 2 to the plasma membrane and are involved in oligomerization. FASEB J (2011) 0.89
Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis (2014) 0.87
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res (2010) 0.87
The design and screening of drugs to prevent acquired sensorineural hearing loss. Expert Opin Drug Discov (2011) 0.85
Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol (2014) 0.85
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther (2013) 0.85
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A (2015) 0.84
Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity. Cell Death Dis (2013) 0.84
Gender difference in Cisplatin-induced nephrotoxicity in a rat model. Nephrourol Mon (2015) 0.82
Role of solute carriers in response to anticancer drugs. Mol Cell Ther (2014) 0.81
Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures. Acta Otolaryngol (2014) 0.81
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
The zebrafish merovingian mutant reveals a role for pH regulation in hair cell toxicity and function. Dis Model Mech (2014) 0.81
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics (2015) 0.80
Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). J Trace Elem Med Biol (2013) 0.80
Anthocyanin - Rich Red Dye of Hibiscus Sabdariffa Calyx Modulates Cisplatin-induced Nephrotoxicity and Oxidative Stress in Rats. Int J Biomed Sci (2013) 0.80
Ancient Chinese Formula Qiong-Yu-Gao Protects Against Cisplatin-Induced Nephrotoxicity Without Reducing Anti-tumor Activity. Sci Rep (2015) 0.80
Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79
Properties and regulation of organic cation transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader-based method. Pflugers Arch (2011) 0.79
A phosphotyrosine switch regulates organic cation transporters. Nat Commun (2016) 0.78
Transport of organic anions and cations in murine embryonic kidney development and in serially-reaggregated engineered kidneys. Sci Rep (2015) 0.78
Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet (2012) 0.78
A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity. Curr Genomics (2016) 0.78
Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B (2016) 0.77
Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury. Am J Physiol Renal Physiol (2012) 0.77
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporter of SLC22A family. Antimicrob Agents Chemother (2016) 0.77
Sensory hair cell death and regeneration in fishes. Front Cell Neurosci (2015) 0.76
NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo. J Hematol Oncol (2016) 0.76
Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules. Pflugers Arch (2014) 0.76
Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res (2016) 0.76
3D Proximal Tubule Tissues Recapitulate Key Aspects of Renal Physiology to Enable Nephrotoxicity Testing. Front Physiol (2017) 0.75
Protective effect of hydroalcoholic extract of tribulus terrestris on Cisplatin induced renal tissue damage in male mice. Int J Prev Med (2015) 0.75
The multifaceted role of the renal microvasculature during acute kidney injury. Pediatr Nephrol (2015) 0.75
Immunohistochemical localization of OCT2 in the cochlea of various species. Laryngoscope (2015) 0.75
Clerosterol from vinegar-baked radix bupleuri modifies drug transport. Oncotarget (2017) 0.75
Cimetidine as an organic cation transporter antagonist. Am J Pathol (2010) 0.75
Phylogenetic, syntenic, and tissue expression analysis of slc22 genes in zebrafish (Danio rerio). BMC Genomics (2016) 0.75
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy. Clin Med Insights Oncol (2016) 0.75
DNA damage response in nephrotoxic and ischemic kidney injury. Toxicol Appl Pharmacol (2016) 0.75
Chemotherapy-induced peripheral neurotoxicity and complementary and alternative medicines: progress and perspective. Front Pharmacol (2015) 0.75
Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity. Antimicrob Agents Chemother (2016) 0.75
Role of transporters in the distribution of platinum-based drugs. Front Pharmacol (2015) 0.75
Ototoxic Model of Oxaliplatin and Protection from Nicotinamide Adenine Dinucleotide. J Otol (2013) 0.75
Systemic Delivery and Biodistribution of Cisplatin in Vivo. Mol Pharm (2016) 0.75
Hydrogen Inhalation Protects against Ototoxicity Induced by Intravenous Cisplatin in the Guinea Pig. Front Cell Neurosci (2017) 0.75
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int (2008) 5.15
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest (2002) 3.48
An improved colorimetric assay for interleukin 2. J Immunol Methods (1986) 3.39
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Organic cation transporters. Rev Physiol Biochem Pharmacol (2003) 1.77
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res (2001) 1.76
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol (2005) 1.73
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2009) 1.56
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr (2006) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol (2003) 1.45
Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos (2005) 1.40
Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett (2006) 1.36
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol (2005) 1.28
A new method for imaging and 3D reconstruction of mammalian cochlea by fluorescent confocal microscopy. Brain Res (2004) 1.25
Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int (2004) 1.24
Transepithelial resistance can be regulated by the intestinal brush-border Na(+)/H(+) exchanger NHE3. Am J Physiol Cell Physiol (2000) 1.14
Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol (2009) 1.06
Organic cation transporters. Xenobiotica (2008) 0.99
Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology (Carlton) (2007) 0.93
Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol (2001) 0.92
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology (1999) 0.91
Best practice in assessing ototoxicity in children with cancer. Eur J Cancer (2004) 0.87
NHE3 Na+/H+ exchanger supports proximal tubular protein reabsorption in vivo. Am J Physiol Renal Physiol (2004) 0.84
Blebs in inner and outer hair cells: a pathophysiological hypothesis. J Laryngol Otol (2008) 0.83
cis-platinum ototoxicity in children. Laryngoscope (1991) 0.79
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia (2010) 5.64
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol (2003) 3.93
Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest (2010) 3.44
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29
A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease. J Am Med Inform Assoc (2005) 3.25
Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab (2010) 3.05
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol (2010) 2.85
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol (2003) 2.69
Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes (2011) 2.65
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 2.49
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest (2012) 2.33
Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A (2006) 2.16
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer (2012) 2.08
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med (2005) 2.01
A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci U S A (2003) 1.98
Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol (2008) 1.95
C-reactive protein makes human endothelium stiff and tight. Hypertension (2010) 1.91
Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol (2006) 1.89
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol (2010) 1.88
NEPH1 defines a novel family of podocin interacting proteins. FASEB J (2002) 1.85
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 1.84
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood (2014) 1.80
Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther (2003) 1.78
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol (2005) 1.73
Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys (2003) 1.70
Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal (2010) 1.70
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Epilepsia (2003) 1.66
Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol (2005) 1.65
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol (2005) 1.63
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol (2005) 1.62
Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int (2009) 1.62
Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol (2005) 1.59
High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int (2012) 1.57
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res (2005) 1.55
Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med (2002) 1.53
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol (2012) 1.51
Synthesis and biologic evaluation of (11)c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters. J Nucl Med (2003) 1.51
The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol (2009) 1.50
Translocation of aquaporin-containing vesicles to the plasma membrane is facilitated by actomyosin relaxation. Biophys J (2007) 1.47
Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med (Berl) (2008) 1.46
Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells (2005) 1.46
Hospital mortality in primary admissions of septic patients with status epilepticus in the United States*. Crit Care Med (2013) 1.46
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol (2003) 1.45
Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy. Pediatr Blood Cancer (2011) 1.44
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial. Pediatr Blood Cancer (2011) 1.43
Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol (2005) 1.43
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother (2005) 1.41
Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J (2013) 1.41
Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatr Blood Cancer (2006) 1.40
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer (2011) 1.40
Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev (2008) 1.39
Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol (2003) 1.39
Does modulation of organic cation transporters improve pralidoxime activity in an animal model of organophosphate poisoning? Crit Care Med (2011) 1.39
Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J Biol Chem (2004) 1.39
Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol (2008) 1.38
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol (2005) 1.37
KIBRA modulates directional migration of podocytes. J Am Soc Nephrol (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 1.34
Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol (2004) 1.34
Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive FAM20A mutations. Nephron Physiol (2013) 1.31
A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res (2002) 1.30
Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol (2008) 1.30
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol (2006) 1.29
Cell death in rheumatoid arthritis. Apoptosis (2009) 1.29
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol (2013) 1.29
Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther (2002) 1.28
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer (2005) 1.27
mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol (2008) 1.27
Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer (2002) 1.25
Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol (2007) 1.24
Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther (2004) 1.24
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci (2005) 1.22
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther (2010) 1.21
The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol (2005) 1.20
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer (2008) 1.18
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17